Evan Lipson, MD

Experts share closing remarks and provide advice for clinicians treating patients with metastatic melanoma.

Dr Michael Atkins and Dr Evan Lipson discuss additional second- and third-line treatment options.

Dr Michael Atkins and Dr Evan Lipson revisit the first patient profile to discuss second- and third-line treatment options for patients with metastatic melanoma.

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

Dr Michael Atkins and Dr Evan Lipson highlight some of the current unmet needs in the treatment of patients with metastatic melanoma.

Experts discuss the use of BRAF and MEK inhibitors as first-line treatments for patients with metastatic melanoma.

Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.

Dr Michael Atkins and Dr Evan Lipson introduce and discuss a patient with unresectable stage IV metastatic melanoma.

Dr Evan Lipson provides a brief overview of metastatic melanoma including information on incidence and prognosis. He also covers the current state of biomarker testing for patients recently diagnosed with metastatic melanoma.